Hunt­ing a T-cell cure for sol­id tu­mors, Rick Klaus­ner’s Lyell steers to Nas­daq — with big dreams and fresh for­tunes on the line

In the 3 years since ex-NCI chief Rick Klaus­ner found­ed Lyell, he’s raised hun­dreds of mil­lions of dol­lars, re­cruit­ed some of the top sci­en­tists in the field of cell ther­a­py 2.0 and al­lied him­self with an ar­ray of big and small ex­plor­ers in­volved in the quest of mas­ter­ing cell ex­haus­tion and dura­bil­i­ty.

Tues­day, though, was a time for throw­ing some dice on Nas­daq, and wait­ing to see how for­tunes could be divvied up in the IPO to come.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER